Methadone maintenance as HIV risk reduction with street-recruited injecting drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 483-489

  Kwiatkowski, Carol F ^a   Booth, Robert E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Drug treatment; HIV risk; Injection drug use; Intervention

Indexed keywords

DIAMORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; DRUG DEPENDENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SELF INJECTION; TREATMENT OUTCOME;

EID: 0035870537     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200104150-00014     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1998;10:1-38.
2. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000;59:17-31.
3. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988;29:214-26.
4. Longshore D, Hsieh S, Danila B, Anglin MD, Methadone maintenance and needle/syringe sharing. Int J Addict 1993;28:983-96.
5. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993;6:1049-56.
6. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994;8:223-31.
7. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend 1996;2:11-20.
8. McLellan AT, Luborsky L. O'Brien CP. Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? Am J Drug Alcohol Abuse 1986;12:101-20.
9. Simpson DD. Treatment for drug abuse: follow-up outcomes and length-of-time spent. Arch Gen Psychiatry 1981;38:875-80.
10. Ball J, Corty E, Bond H, Myers C, Tommasello A. The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res Monogr 1981;81:224-30.
11. Bell J, Hall W, Byth K. Changes in criminal activity after entering methadone maintenance. Br J Addict 1992;87:251-8.
12. Dole VP, Nyswander ME, Warner A. Successful treatment of 750 criminal addicts. JAMA 1968;206:2708-11.
13. Hunt DE, Lipton DS, Spunt B. Patterns of criminal activity among methadone clients and current narcotics users not in treatment. J Drug Issues 1984;Fall:687-702.
14. Rounsaville BJ, Kosten TR, Kleber HD. The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5 year follow-up study. Am J Drug Alcohol Abuse 1987;3:213-29.
15. Stimmel B, Goldberg J, Cohen M, Rotkopf E. Detoxification from methadone maintenance: risk factors associated with relapse to narcotic use. Ann NY Acad Sci 1978;311:173-80.
16. DeLeon G, Andrews MPA, Wexler HK, Jaffee J, Rosenthal MS. Therapeutic community dropouts: criminal behavior five years after treatment. Am J Drug Alcohol Treat 1979;6:253-71.
17. Simpson DD. The relation of time spent in drug abuse treatment to post-treatment outcome. Am J Psychiatry 1979;136:1449-53.
18. Schuster CR. Intravenous drug use and HIV prevention. Public Health Rep 1988;103:261-6.
19. Brickner PW, Torres RA, Barnes M, et al. Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Ann Intern Med 1989;110: 833-7.
20. Brown BS, Beschner GM. AIDS and HIV infection - implications for drug abuse treatment. J Drug Issues 1989;19:141-62.
21. Booth RE, Kwiatkowski CF, Iguchi MY, Pinto F, John D. Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep 1998;13:116-28.
22. Dennis ML, Ingrain PW, Burks ME, Rachal JV. Effectiveness of streamlined admissions to methadone treatment: a simplified time series analysis. J Psychoactive Drugs 1994;26:207-16.
23. Festinger DS, Lamb RJ, Kirby KC, Marlowe DB. The accelerated intake: a method for increasing initial attendance to outpatient cocaine treatment. J Appl Behav Anal 1996;29:387-9.
24. Woody G, O'Hare K, Mintz J, O'Brien C. Rapid intake: a method for increasing retention rate of heroin addicts seeking methadone treatment. Compr Psychiatry 1975;16:165-9.
25. Mejta CL, Bokos PJ, Mickenberg J, Maslar ME, Senay E. Improving substance abuse treatment access and retention using a case management approach. J Drug Issues 1997;27:329-40.
26. Siegal HA, Rapp RC, Li L, Sana P, Kirk KD. The role of case management in retaining clients in substance abuse treatment: an exploratory analysis. J Drug Issues 1997;7:821-31.
27. Bux DA, Iguchi MY, Lidz V, Baxter RC, Platt JJ. Participation in a coupon distribution program for free methadone detoxification. Hosp Commun Psychiatry 1993;44:1066-72.
28. Jackson JF, Rotkiewicz LG, Quinones MA, Passannante MR. A coupon program - drug treatment and AIDS education. Int J Addict 1989;24:1035-51.
29. Sorensen JL, Costantini MF, Wall TL, Gibson DR. Coupons attract high-risk untreated heroin users into detoxification. Drug Alcohol Depend 1993;31:247-52.
30. Wells EA, Fleming C, Calsyn DA, Jackson TR, Saxon AJ. Users of free treatment slots at a community-based methadone maintenance clinic. J Subst Abuse Treat 1995;12:13-8.
31. Maddux JF, Prihoda TJ, Desmond DP. Treatment fees and retention on methadone maintenance. J Drug Issues 1994;24:429-43.
32. DeJarlais DC. Retention rates among New York City methadone patients: a response to Bayer and Koenigsberc [letter]. Int J Addict 1982;17:929-30.
33. Dowling-Guyer S, Johnson ME, Fisher DG, et al. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment 1994;1:383-92.
34. Weatherby NL, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Evaluation Program Planning 1994;17:347-55.
35. Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions for out-of-treatment injection drug users. J Psychoactive Drugs 1998;30:269-78.
36. Colon HM, Robles RR, Freeman D, Matos T. Effects of a HIV risk reduction education program among injection drug users in Puerto Rico. Puerto Rico Health Sci J 1993;12:27-33.
37. McCusker J, Stoddard AM, Zapka JG, Morrison CS, Zorn M, Lewis BF. AIDS education for drug abusers: evaluation of short-term effectiveness. Am J Public Health 1992;82:533-40.
38. Siegal HA, Falck RS, Carlson RG, Wang J. Reducing HIV needle risk behaviors among injection-drug users in the Midwest: an evaluation of the efficacy of standard and enhanced interventions. AIDS Educ Prev 1995;7:308-19.
39. Stephens RC, Kwiatkowski CF, Booth RE. The impact of the NIDA cooperative agreement programs on HIV risk among crack and injection drug users. In: Emergent issues in the field of drug abuse. Levy JA, Stephens RC, McBride DC, eds. Greenwich, CT: JAI Press, 2000:241-59.
40. Kwiatkowski CF, Booth RE. ASPD measurement strategies to predict HIV risk among injection drug users. Presented at the College on Problems of Drug Dependence conference, Acapulco, June 1999.
41. Magura S, Goldsmith DS, Casriel C, Goldstein PJ, Lipton DS. The validity of methadone clients' self-reported drug use. Intern J Addict 1987;22:727-49.
42. Maisto SA, McKay JR, Connors GJ. Self-report issues in substance abuse: state of the art and future directions. Behav Assess 1990; 121:117-34.